抗栓治疗在显著降低急性冠脉综合征患者不良心血管事件发生率的同时,也增加了出血的风险。大出血往往增加患者死亡率及再发缺血事件,影响临床预后。肾功能不全、低体重等是出血的危险因素,针对患者情况进行个性化抗栓治疗或引进应用新型抗栓药物,可能会减少出血并发症。 Antithrombotic therapy, while significantly reducing the incidence of adverse cardiovascular events in patients with acute coronary syndrome, also increased the risk of bleeding. Bleeding often increases patient mortality and recurrent ischemic events, affecting clinical outcomes. Renal insufficiency, low body weight and other risk factors for bleeding, personalized antithrombotic therapy for patients or the introduction of new antithrombotic drugs, may reduce bleeding complications.